



Update on the Management of Inflammatory Breast Cancer

An Essay

*Submitted for Partial Fulfillment of Master
Degree in General Surgery*

Presented by
Mustafa Sultan Mustafa
M.B.B.ch
Al Azhar University

Supervised by
Prof. Dr. Khaled Abd Allah Alfeky
Professor & Head of General Surgery
Faculty of Medicine
Ain Shams University

Dr. Mohammed Attia Mohammed
Assistant professor of General Surgery
Faculty of Medicine
Ain Shams University

Faculty of Medicine
Ain Shams University
2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبَدَانِكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the
Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound
gratitude to **Prof. Dr. Khaled Abd Allah Alfeiky**,
Professor & Head of General Surgery Faculty of Medicine Ain
Shams University for his keen guidance, kind supervision,
valuable advice and continuous encouragement, which made
possible the completion of this work.*

*I am also delighted to express my deepest gratitude and
thanks to **Dr. Mohammed Attia Mohammed**, Assistant
professor of General Surgery Faculty of Medicine Ain Shams
University, for his kind care, continuous supervision, valuable
instructions, constant help and great assistance throughout
this work.*

Mustafa Sultan Mustafa

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	v
Introduction	1
Aim of the Work	5
Anatomy of the Breast	6
Epidemiology	14
Pathophysiology	23
Diagnosis	31
Prognostic Factors in Breast Cancer	57
Treatment	65
Prognosis and Outcome	132
Summary & Conclusion	136
References	140
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Classification of breast cancer subtypes by AJCC and SEER EOD staging	21
Table (2):	Differential Diagnosis of IBC	37
Table (3):	A comparison of the clinico, pathological features of inflammatory breast cancer (IBC), primary breast lymphoma (PBL) and axillary lymphoma presenting as IBC (AL).....	41
Table (4):	TNM staging of inoperable LABC/IBC.....	56
Table (5):	Proposed mechanisms of <i>trastuzumab</i> action and resistance.	80
Table (6):	Types of Mastectomies Used as Treatments for Breast Cancer	95
Table (7):	Examples of Commonly Used Endocrine Regimens in the Metastatic Setting.	122
Table (8):	Examples of Commonly Used chemotherapeutic Regimens in Metastatic Breast Cancer.....	124
Table (9):	Breast Cancer Follow-Up	135

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Anatomy of the breast.....	7
Fig. (2):	Blood supply, lymphatics and innervation of the breast	8
Fig. (3):	Lymphatic Drainage of the Breast.....	12
Fig. (4):	Anatomy of axilla.	13
Fig. (5):	Inflammatory breast cancer with a characteristic tumor embolus in a dermal lymphatic channel (A) and strong and crisp membranous staining for E-cadherin in the intralymphatic tumor cells (B). Magnification: ×20.....	25
Fig. (6):	Primary inflammatory breast cancer with classic invasive lobular carcinoma histology composed of files of small malignant cells, some of which have signet-ring cell features	26
Fig. (7):	IBC with skin overlying the breast showing a pink or mottled pink hue.....	33
Fig. (8):	IBC with thickening of the skin.....	34
Fig. (9):	IBC with breast enlargement, Peau d'orange, thickening of the skin, diffuse erythema and oedema.....	35
Fig. (10):	Another example of IBC with breast enlargement, Peau d'orange, thickening of the skin, diffuse erythema and oedema.	36
Fig. (11):	Differential Diagnosis of IBC.	37
Fig. (12):	Patient with Cellulitis of the breast.	39
Fig. (13):	Patient with primary non-Hodgkins lymphoma (NHL) of the breast.....	40

List of Figures Cont...

Fig. No.	Title	Page No.
Fig. (14):	Patient with Idiopathic granulomatous mastitis.....	41
Fig. (15):	Inspection of the breast (a) From the front and (b) With arms raised.....	43
Fig. (16):	Palpation of the breast, (c) Palpation of the breast with the patient supine and (d) Palpation of the axilla.....	44
Fig. (17):	Showing how to make breast self-examination.....	45
Fig. (18):	Showing Techniques for mammography.....	46
Fig. (19):	Showing the Digital mammography.....	46
Fig. (20):	47-year-old woman who presented with 2-month history of breast erythema, ridging, peau d'orange, and poorly defined 6 x 5 cm palpable mass in right upper inner quadrant extending into right lower inner quadrant.....	47
Fig. (21):	Trabecular thickening in 60-year-old woman with breast carcinoma who presented with axillary lymphadenopathy.....	48
Fig. (22):	Inflammatory carcinoma of the breast with mass in 57-year-old woman who presented with erythema of right breast and slight nipple inversion.....	49
Fig. (23):	Sonography showing breast mass.	50
Fig. (24):	MRI of the breast in a patient with IBC.....	52
Fig. (25):	PET/CT scan showing a <i>left</i> locally advanced breast cancer that has widespread distant metastases.	54
Fig. (26):	Treatment algorithm for inflammatory breast cancer.....	67

List of Figures Cont...

Fig. No.	Title	Page No.
Fig. (27):	Drawing reproduced from The Stehlin Foundation for Cancer Research September 2003 newsletter.....	72
Fig. (28):	Showing the Alopecia as a complication of chemotherapy.....	92
Fig. (29):	Showing the Modified radical mastectomy.	94
Fig. (30):	Showing Types of mastectomies.	96
Fig. (31):	Showing Sentinel Node Biopsy.	98
Fig. (32):	Images of radiation treatment fields to treat the chest wall and internal mammary lymph nodes.....	102
Fig. (33):	Images of radiation treatment fields using a match electron field technique to treat the chest wall and internal mammary lymph nodes....	103
Fig. (34):	Image of a radiation treatment field used to treat the axillary apex/supraclavicular fossa	103
Fig. (35):	Showing Lymphedema as a complication of radiotherapy.	105
Fig. (36):	Showing Dermatitis due to Radiotherapy.	109
Fig. (37):	Surgical oopherctomy.....	112

List of Abbreviations

Abb.	Full term
ADCC.....	Antigen-dependent cellular cytotoxicity
AJCC.....	American Joint Committee on Cancer
AL	Axilliary lymphoma
Anti-VEGF.....	Anti-Vascular endothelial growth factor
ASCO	American Society of Clinical Oncology
ATP	Adenosine 5-triphosphate
bFGF.....	Basic fibroblast growth factor
CAM.....	Complementary and alternative medicine
CAP.....	College of American Pathologists
CIA.....	Chemotherapy-induced amenorrhea
CMF.....	Cyclophosphamide / methotrexate / 5-fluorouracil
CNS.....	Central nervous system
CT	Computed tomography
EGFR.....	Epidermal growth factor receptor
EOD- E	Extent of Disease – Extent
EOD	Extent of disease
EOD-S.....	Extent of disease-size
ER	Estrogen-receptor
FDA	Food and Drug Administration
FISH	Fluorescence in-situ hybridization
FTIs	Farnesyltransferase inhibitors
GCR	Gharbiah cancer registry
GISTs.....	Gastrointestinal stromal tumors
GnRH.....	Gonadotropin-releasing hormone
HER2	Human Epidermal Receptor Type 2

List of Abbreviations Cont...

Abb.	Full term
IBC.....	Inflammatory breast cancer
IBCSG.....	International Breast Cancer Study Group
IGF1R	Insulin-like growth factor 1 receptor
JNM	Journal of Nuclear Medicine
LABC	Locally advanced breast cancer
MoAbs	Monoclonal antibodies
MRI	Magnetic resonance imaging
MTD.....	Maximum Tolerated Dose
MTT	Molecular targeted therapy
MVD.....	Microvessel density
N/A.....	Not applicable
NCI	National Cancer Institute
NF-kB	Nuclear factor-kappaB
NHL	Non-Hodgkins lymphoma
OFS.....	Ovarian function suppression
PBL	Primary breast lymphoma
PDGFR	Platelet-derived growth factor receptor
PET	Positron Emission Tomography
PEV.....	Poussee Evolutive
PR	Progesterone receptor
PTEN	Phosphatase and tensin homologue
SEER	Surveillance, Epidemiology, and End-Results
TGF- α	Transforming growth factor- α
UICC.....	Union International Contre le Cancer
VEGF	Vascular endothelial growth factor
WO/WO.....	Week-on/week-off



Introduction

INTRODUCTION

Inflammatory breast cancer is a rare and aggressive form of invasive breast cancer accounting for 2.5% of all breast cancer cases. Historically, IBC is a lethal disease with less than a 5% survival rate beyond 5 years when treated with surgery or radiation. In general, women with IBC presented at a younger age are more likely to have a metastatic disease at diagnosis, have shorter survival than women with non IBC. Although survival times have increased with multimodal therapy, they are still around 35% to 40 % and much lower than those for other breast cancer^[1].

Inflammatory breast cancer is most frequently characterized by a very rapid onset of clinical signs and symptoms. Because of the possibility of mistaking IBC for a benign bacterial infection such as mastitis, it is important to note that IBC is not a true inflammatory process and is generally not associated with symptoms such as fever, localized pain, or leukocytosis. In the majority of patients with IBC, no discrete mass is palpable on clinical examination. Rapid breast enlargement and changes in the skin overlying the breast are usually the first manifestations of the disease. Early erythematous discoloration of the skin can further progress to intense red or purple color involving the entire breast. Specifically associated skin manifestation is the peau-d'orange or orange peel appearance attributed to the underlying skin edema. The rapid progression, along with

diffuse erythema of more than one-third of skin over lying the breast, distinguishes IBC From neglected LABC with skin involvement ^[2]. In the seven edition of American Joint Committee on Cancer staging guidelines for breast cancer, IBC is classified as stage IIIB,IIIC, or even IV, depending on nodal status and evidence of metastasis ^[3].

Inflammatory breast cancer is the most aggressive and fatal form of invasive breast cancer. The median overall survival duration among woman with IBC is less than 5years even with multimodality treatment option. There are few established risk factor for IBC. However, many distinguishable epidemiologic characteristics of IBC have been studied. The risk factor with the strongest association with IBC include the higher incidence evident in African American ethnicity, high body mass index, and younger age at disease onset^[4].

Inflammatory breast cancer is a rare and aggressive variant of LABC. Although the disease is characterized by specific clinical manifest tation already described, it is not a specific histological sub type of mammary carcinoma. The presence of pertinent histo pathological finding in the mammary parenchyma and over lying skin, however, in conjunction with the characteristic clinical history, can allow the pathologist to suggest a diagnosis of IBC. The pathognomonic feature that distinguishes IBC from the commonly encountered LABC type is the presence of

numerous dermal tumor emboli in the papillary and reticular dermis of skin over lying the breast ^[5].

Breast tumors are categorized into specific subtypes on the basis of the presence or absence of estrogen and progesterone receptors, the level of expression of claudins, the presence and extent of amplification of the Her2 oncogene, and the differential production of cytokeratin. Although IBCs may possess any combination of hormone receptors and oncogenes, they are most often classified within the Her2 amplified, basal like, breast cluster and may also be low in claudin. This classification of IBC tumors is consistent with previous gene expression studies reporting that IBC tumors commonly lack ER/PR and have Her2 oncogene amplification^[6]. Other characteristics of IBC tumors include high expression of the tumor suppressor P53 and over expression of the epidermal growth factor receptor (EGFR), which are both associated with poor prognosis^[7].

The key roles of imaging in IBC are to identify primary breast tumor and facilitate image-guided diagnostic biopsy to enable the optimal evaluation of biomarkers, stage local regional disease, diagnose distant metastases, evaluate tumor response to neoadjuvant therapy. Standard breast imaging modalities, such as mammography and ultrasound, clinical staging and therapeutic monitoring of breast cancer, but newer modalities such as magnetic resonance imaging, hybrid positron emission

tomography/computed tomography are being used more frequently^[8].

The management of IBC has substantially evolved in the past 3 decades. Surgery was the first therapeutic modality used, but it had disappointing results. The mean survival of patients treated with mastectomy alone ranged from 12 to 32 months. The addition of radiotherapy improved the locoregional control rate, but it had no significant effect on survival^[9]. Presently, the standard of care requires having a team of dedicated and experienced specialists (pathologist, surgeon, radiotherapist, and medical oncologist) involved in the complex management of this entity. The treatment of IBC is clearly outlined in sequence, with neoadjuvant chemotherapy representing the mainstay of treatment. Locoregional treatment includes radiotherapy with or without surgery and continues to play a major role after systemic treatment. Its sequence is greatly dependent on the quality of objective response achieved with induction chemotherapy. In the majority of cases, after optimal remission, and resolution of skin changes, patients are considered surgical candidates and a modified radical mastectomy is recommended followed by radiotherapy^[10].